Další formáty:
BibTeX
LaTeX
RIS
@article{837992,
author = {Doubek, Michael and Palásek, Ivo and Pospíšil, Zdeněk and Borský, Marek and Klabusay, Martin and Brychtová, Yvona and Jurček, Tomáš and Ježíšková, Ivana and Krejčí, Marta and Dvořáková, Dana and Mayer, Jiří},
article_number = {6},
doi = {http://dx.doi.org/10.1016/j.exphem.2009.03.004},
keywords = {MINIMAL RESIDUAL DISEASE; POLYMERASE-CHAIN-REACTION; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RT-PCR; GEMTUZUMAB OZOGAMICIN; FUSION TRANSCRIPTS; PROGNOSTIC VALUE; CANCER PROGRAM; BONE-MARROW},
language = {eng},
issn = {0301-472X},
journal = {Experimental Hematology},
title = {Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression},
volume = {37},
year = {2009}
}
TY - JOUR
ID - 837992
AU - Doubek, Michael - Palásek, Ivo - Pospíšil, Zdeněk - Borský, Marek - Klabusay, Martin - Brychtová, Yvona - Jurček, Tomáš - Ježíšková, Ivana - Krejčí, Marta - Dvořáková, Dana - Mayer, Jiří
PY - 2009
TI - Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression
JF - Experimental Hematology
VL - 37
IS - 6
SP - 659-672
EP - 659-672
PB - Elsevier
SN - 0301472X
KW - MINIMAL RESIDUAL DISEASE
KW - POLYMERASE-CHAIN-REACTION
KW - ACUTE PROMYELOCYTIC LEUKEMIA
KW - ACUTE LYMPHOBLASTIC-LEUKEMIA
KW - RT-PCR
KW - GEMTUZUMAB OZOGAMICIN
KW - FUSION TRANSCRIPTS
KW - PROGNOSTIC VALUE
KW - CANCER PROGRAM
KW - BONE-MARROW
N2 - Objective. Our objective was to determine the value of frequent minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) as a robust marker of impending relapse, and whether treatment benefits patients during the MRD-positive phase of their disease. Materials and Methods. Frequent MRD monitoring was performed in all AMI, treatment phases using real-time quantitative polymerase chain reaction for fusion transcripts (CBFB/MYH11; RUNX1/RUNX1T1 fusion transcripts of MLL gene) and for the Wilms' tumor (WT1) gene. A total of 2,664 samples, taken from 79 AML patients and 6 healthy volunteers, were examined. Presence of fusion gene was detected in 25 of 79 examined patients. Results. Vast correlation was discovered for fusion transcripts as well as for the 1471 gene between levels in bone marrow (BM), peripheral blood, CD34(+) BM cells, and CD34(-) BM cells. WT1 expression, however, was usually positive for cases showing fusion transcripts negativity and in health), volunteers. Moreover, no universal value of the WT1 expression could unequivocally discriminate between remission and relapse. Therefore, detection of molecular relapses relied on fusion transcripts only and was characterized by strong expression in CD34(+) cells. Considering relapsed patients, duration from molecular to hematological relapse was 8 to 79 days (median: 25.5 days). Twelve patients were treated (chemotherapy, gemtuzumab ozogamicin, or immunomodulation after allogeneic transplantation) for 21 molecular relapses and 14 responses to treatment were observed. Conclusions. Frequent quantitative monitoring of fusion transcripts is useful for reliably predicting hematological relapse in AML patients. Treatment for molecular relapse of AML can be successful.
ER -
DOUBEK, Michael, Ivo PALÁSEK, Zdeněk POSPÍŠIL, Marek BORSKÝ, Martin KLABUSAY, Yvona BRYCHTOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marta KREJČÍ, Dana DVOŘÁKOVÁ a Jiří MAYER. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. \textit{Experimental Hematology}. Elsevier, 2009, roč.~37, č.~6, s.~659-672, 4 s. ISSN~0301-472X. Dostupné z: https://dx.doi.org/10.1016/j.exphem.2009.03.004.
|
